Most Read Articles
27 Jan 2018
There is an over-representation of women in published reports of celecoxib drug-induced liver injury (DILI), according to a recent study. Latency has been shown to be short (<3 months) in most patients, but some of them may present with DILI after prolonged use of celecoxib.
22 Mar 2016
A recent study showed that routine use of alpha galactosidase (AG) has no benefit in irritable bowel syndrome (IBS) patients.
15 Nov 2017
Both hatha yoga and a low-FODMAP (Fermentable, Oligo-, Di-, Monosaccharides and Polyol) diet can alleviate gastrointestinal symptoms, as well as improve a range of other psychological and physiological health parameters, in patients with irritable bowel syndrome (IBS), a study has shown.
Rachel Soon, 14 Dec 2016

More well-designed studies are needed to confirm the benefits of various probiotics currently promoted for gut health, according to experts.

Complete endoscopic resection may not be suitable as sole therapy for Barrett’s oesophagus

13 Feb 2018

Complete endoscopic resection (CER) of Barrett’s oesophagus (BE) results in a complete eradication rate of 85 percent, with nearly 6-percent recurrent rate of neoplasia, reports a recent study. Additionally, the estimated rate of postprocedural stricture was 37.4 percent.

A total of eight studies involving 676 patients (high-grade dysplasia, 54 percent) met the inclusion criteria.

The pooled estimated rates were 85.0 percent (95 percent CI, 79.4‒89.2 percent) for complete eradication of intestinal metaplasia and 96.6 percent (94.0‒98.1 percent) for complete eradication of intestinal neoplasia. Recurrence rates of intestinal metaplasia and neoplasia were 15.7 percent (8.0‒28.4 percent) and 5.8 percent (3.9‒8.6 percent), respectively.

Estimated incidences of adverse events were as follows: stricture (37.4 percent; 24.4‒52.6 percent), bleeding (7.9 percent; 4.4‒13.8 percent) and perforation (2.3 percent; 1.3‒4.1 percent).

“On the basis of this high rate of adverse events and significant heterogeneity in the studies included, the present meta-analysis cannot endorse CER as sole therapy for BE,” the investigators said.

To report the rate of eradication and recurrence of both neoplasia and intestinal mucosa, as well as the rate of adverse events for CER of BE, the investigators conducted a systematic review and meta-analysis of cohort studies that reported the clinical outcome of patients with BE who underwent CER and had at least 15-month follow-up after the time of elimination of BE.

Main outcomes included pooled estimated rates of complete eradication of intestinal metaplasia and neoplasia, recurrence of intestinal metaplasia and neoplasia, and incidence of oesophageal stricture, bleeding and perforation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Jan 2018
There is an over-representation of women in published reports of celecoxib drug-induced liver injury (DILI), according to a recent study. Latency has been shown to be short (<3 months) in most patients, but some of them may present with DILI after prolonged use of celecoxib.
22 Mar 2016
A recent study showed that routine use of alpha galactosidase (AG) has no benefit in irritable bowel syndrome (IBS) patients.
15 Nov 2017
Both hatha yoga and a low-FODMAP (Fermentable, Oligo-, Di-, Monosaccharides and Polyol) diet can alleviate gastrointestinal symptoms, as well as improve a range of other psychological and physiological health parameters, in patients with irritable bowel syndrome (IBS), a study has shown.
Rachel Soon, 14 Dec 2016

More well-designed studies are needed to confirm the benefits of various probiotics currently promoted for gut health, according to experts.